Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB -1.79%37 3-Year Book Growth Rate is -72.80% as of Jun. 2026. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $34.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,123 Biotechnology companies, HCW Biologics ranks worse than 95.19% on this metric.
During the past 3 years, the average Book Value per Share Growth Rate was -72.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of HCW Biologics was -72.80% per year. The lowest was -72.80% per year. And the median was -72.80% per year.
HCW Biologics (NAS:HCWB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
HCW Biologics 3-Year Book Growth Rate Related Terms
HCWB vs AAGH, ACXP, ENVB: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, HCW Biologics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where HCW Biologics's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -72.80% mean?
HCW Biologics (HCWB) has a 3-Year Book Growth Rate of -72.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #1069 out of 1123 companies in the Biotechnology industry, placing it in the top 95.2%.
Is HCW Biologics' 3-Year Book Growth Rate too high?
HCW Biologics' current 3-Year Book Growth Rate is -72.80%. Based on the distribution chart, HCW Biologics ranks #1069 out of 1123 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' 3-Year Book Growth Rate compare to AAGH and ACXP?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #1069 out of 1123 companies for 3-Year Book Growth Rate. This places HCW Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for HCW Biologics and its competitors. HCW Biologics's current 3-Year Book Growth Rate is -72.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $34.74, compared to a current price of $2.20 — trading 93.7% below its estimated fair value. The current 3-Year Book Growth Rate is -72.80%. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For HCW Biologics (HCWB), the current 3-Year Book Growth Rate is -72.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $2.20 is trading 93.7% below its estimated GF Value™ of $34.74.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
3-Year Book Growth Rate: -72.80%
GF Value™: $34.74 vs. price of $2.20 (93.7% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
